Lipoprotein-associated phospholipase A2 (Lp-PLA-2): A novel and promising biomarker for cardiovascular risks assessment

Disease Markers

Volumn 34, Issue 5, 2013, Pages 323-331

  Cai, Anping ^a   Zheng, Dongdan ^b   Qiu, Ruofeng ^b   Mai, Weiyi ^b   Zhou, Yingling ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

cardiovascular diseases; inflammatory biomarker; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; DARAPLADIB;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 84878882809     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-130976     Document Type: Review

References (84)

1. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association guide for improving cardiovascular health at the community level: A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation. 2003. 107(4): 645-51.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999. 340(2): 115-26.
3. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol. 2001. 88(7B): 3J-6J.
4. Libby P. Act local, act global: Inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol. 2005. 45(10): 1600-2.
5. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008. 101(12A): 51F-57F.
6. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003. 107(3): 499-511.
7. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoproteinassociated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000. 343(16): 1148-55.
8. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008. 101(12A): 41F-50F.
9. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoproteinassociated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999. 19(12): 2909-17.
10. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006. 26(7): 1586-93.
11. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004. 110(14): 1903-8.
12. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. downloaded. Arterioscler Thromb Vasc Biol. 2006. 26(11): 2517-22.
13. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007. 27(11): 2463-9.
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106(25): 3143-421.
15. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middleagedmen and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004. 109(7): 837-42.
16. Nambi V, Hoogeveen RC, Chambless L, et al. Lipoproteinassociated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009. 40(2): 376-81.
17. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008. 51(17): 1632-41.
18. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008. 118(11): 1172-82.
19. Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoproteinassociated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLOS ONE. 2011. 6(8): e23425.
20. Wilensky RL, Shi Y, Mohler ER 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. NatMed. 2008. 14(10): 1059-66.
21. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002. 91(4): 281-91.
22. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: Potential therapeutic role for immunomodulation. Curr Opin Cardiol. 2007. 22(6): 545-51.
23. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation. 2007. 116(16): 1832-44.
24. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation. 2001. 103(22): 2705-10.
25. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoproteinassociated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006. 26(11): 2523-9.
26. Herrmann J, Mannheim D, Wohlert C, et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 2009. 30(23): 2930-8.
27. Mannheim D, Herrmann J, Versari D, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008. 39(5): 1448-55.
28. Dada N, Kim NW, Wolfert RL. Lp-PLA2: An emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002. 2(1): 17-22.
29. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007. 115(21): 2715-21.
30. Wu X, McIntyre TM, Zimmerman GA, Prescott SM, Stafforini DM. Molecular characterization of the constitutive expression of the plasma platelet-activating factor acetylhydrolase gene in macrophages. Biochem J. 2003. 375(Pt 2): 351-63.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl JMed. 1997. 336(14): 973-9.
32. Dada N, Kim NW, Wolfert RL. Lp-PLA2: An emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002. 2(1): 17-22.
33. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988. 85(8): 2805-9.
34. Khuseyinova N, Greven S, Ruckerl R, et al. Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: Results from the AIRGENE Study Center Augsburg. Clin Chem. 2008. 54(1): 124-30.
35. Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study. Atherosclerosis. 2008. 199(1): 110-5.
36. CaslakeMJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease. Atherosclerosis. 2000. 150(2): 413-9.
37. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet. 2010. 375(9725): 1536-44.
38. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc. 2007. 82(2): 159-65.
39. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoproteinassociated phospholipase A2: Review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006. 9(3): 138-43.
40. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005. 26(2): 137-44.
41. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007. 53(8): 1440-7.
42. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Highsensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006. 166(19): 2073-80.
43. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001. 69(3): 89-95.
44. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010. 160(4): 655-61.
45. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLIDTIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011. 162(4): 613-619. e1.
46. Macphee CH. Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001. 1(2): 121-5.
47. Turunen P, Jalkanen J, Heikura T, et al. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. J Lipid Res. 2004. 45(9): 1633-9.
48. Jang Y, Waterworth D, Lee JE, et al. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males. PLOS ONE. 2011. 6(4): e18208.
49. MacPhee CH, Moores KE, Boyd HF, et al. Lipoproteinassociated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J. 1999. 338 ( Pt 2): 479-87.
50. May HT, Horne BD, Anderson JL, et al. Lipoproteinassociated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006. 152(5): 997-1003.
51. Anderson JL. Lipoprotein-associated phospholipase A2: An independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008. 101(12A): 23F-33F.
52. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988. 85(8): 2805-9.
53. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A(2): Role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011. 2(1): 27-38.
54. Benitez S, Camacho M, Arcelus R, et al. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis. 2004. 177(2): 299-305.
55. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007. 191(1): 54-62.
56. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995. 374(6522): 549-53.
57. Morgan EN, Boyle EM Jr, Yun W, et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation. 1999. 100(19 Suppl): II365-8.
58. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J. 2000. 14(13): 2032-9.
59. Noto H, Hara M, Karasawa K, et al. Human plasma plateletactivating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol. 2003. 23(5): 829-35.
60. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAFacetylhydrolase in patients with coronary artery disease: Results of a cross-sectional analysis. J Lipid Res. 2003. 44(7): 1381-6.
61. Hoffmann MM, Winkler K, Renner W, et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost. 2009. 7(1): 41-8.
62. Hou L, Chen S, Yu H, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: The Beijing atherosclerosis study. Hum Genet. 2009. 125(1): 11-20.
63. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis. 2003. 168(2): 283-8.
64. Wang T, Karino K, Yamasaki M, et al. Effects of G994T in the Lp-PLA2 gene on the plasma oxidized LDL level and carotid intima-media thickness in Japanese: the Shimane study. Am J Hypertens. 2009. 22(7): 742-7.
65. Li L, Qi L, Lv N, et al. Association between lipoproteinassociated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population. Ann Hum Genet. 2011. 75(5): 605-11.
66. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994- T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 1998. 47(2): 177-81.
67. Shimokata K, Yamada Y, Kondo T, et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis. 2004. 172(1): 167-73.
68. Jang Y, Kim OY, Koh SJ, et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab. 2006. 91(9): 3521-7.
69. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004. 13(13): 1341-51.
70. Liu PY, Li YH, Wu HL, et al. Platelet-activating factoracetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost. 2006. 4(5): 1023-8.
71. Casas JP, Ninio E, Panayiotou A, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation. 2010. 121(21): 2284-93.
72. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 350(15): 1495-504.
73. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001. 38(5): 1302-6.
74. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation. 2001. 103(22): 2705-10.
75. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001. 38(5): 1302-6.
76. Oei HH, der Meer IM v, Hofman A, et al. Lipoproteinassociated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation. 2005. 111(5): 570-5.
77. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middleaged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007. 27(6): 1411-6.
78. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: The Rancho Bernardo Study. J Am Coll Cardiol. 2008. 51(9): 913-9.
79. Tsimikas S, Willeit J, Knoflach M, et al. Lipoproteinassociated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: Results from the Bruneck study. Eur Heart J. 2009. 30(1): 107-15.
80. Jenny NS, Solomon C, Cushman M, et al. Lipoproteinassociated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study. Atherosclerosis. 2010. 209(2): 528-32.
81. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005. 26(2): 137-44.
82. Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005. 182(1): 181-8.
83. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006. 26(7): 1586-93.
84. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008. 28(6): 1172-8.